
Cantel Medical Corp. CMD
Cantel Medical Corp. Income Statement 2011-2026 | CMD
Annual Income Statement Cantel Medical Corp.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.27 B | 3.84 B | 3.98 B | 3.28 B | 3.14 B | 2.08 B | 1.49 B | 1.07 B | 707 M | 425 M |
Shares |
42.2 M | 41.8 M | 41.7 M | 41.7 M | 41.6 M | 41.6 M | 40.8 M | 41.1 M | 40.7 M | 38.9 M |
Net Income |
13.7 M | 55 M | 91 M | 71.4 M | 60 M | 48 M | 43.3 M | 39.2 M | 31.3 M | 20.4 M |
Revenue |
1.02 B | 918 M | 872 M | 770 M | 665 M | 565 M | 489 M | 425 M | 386 M | 322 M |
EBITDA |
123 M | 126 M | 156 M | 144 M | 122 M | 105 M | 89.8 M | 80.5 M | 68 M | 43.8 M |
Operating Expenses |
388 M | 344 M | 292 M | 257 M | 212 M | 173 M | 142 M | 120 M | 112 M | 91.4 M |
General and Administrative Expenses |
198 M | 172 M | 138 M | 122 M | 97.5 M | 77.9 M | 65 M | 53.2 M | 47.6 M | 40.7 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cantel Medical Corp. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 21.07 | 1.81 % | $ 10.7 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 202.8 | -1.16 % | $ 58.3 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.03 | -1.95 % | $ 162 M | ||
|
Alcon
ALC
|
$ 80.27 | -0.43 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 41.66 | -1.76 % | $ 1.96 B | ||
|
electroCore
ECOR
|
$ 5.62 | 11.73 % | $ 31 K | ||
|
AngioDynamics
ANGO
|
$ 9.97 | -0.8 % | $ 407 M | ||
|
The Cooper Companies
COO
|
$ 83.71 | 0.69 % | $ 16.7 B | ||
|
Haemonetics Corporation
HAE
|
$ 82.2 | -2.19 % | $ 4.14 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.64 | -1.79 % | $ 27.1 M | ||
|
Glaukos Corporation
GKOS
|
$ 113.09 | -0.93 % | $ 5.48 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
ICU Medical
ICUI
|
$ 151.86 | 0.14 % | $ 3.7 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.61 | -4.01 % | $ 178 M | ||
|
iRhythm Technologies
IRTC
|
$ 180.4 | -4.68 % | $ 5.63 B | ||
|
Repro Med Systems
KRMD
|
$ 5.67 | -2.41 % | $ 259 M | ||
|
LeMaitre Vascular
LMAT
|
$ 84.83 | -0.25 % | $ 1.9 B | ||
|
Intuitive Surgical
ISRG
|
$ 587.18 | 0.36 % | $ 209 B | ||
|
Masimo Corporation
MASI
|
$ 140.04 | 1.54 % | $ 7.46 B | ||
|
Merit Medical Systems
MMSI
|
$ 86.37 | -7.31 % | $ 5.03 B | ||
|
Microbot Medical
MBOT
|
$ 2.08 | -5.02 % | $ 21.2 M | ||
|
Nephros
NEPH
|
$ 4.89 | -2.5 % | $ 50.8 M | ||
|
Milestone Scientific
MLSS
|
$ 0.3 | 1.23 % | $ 23.9 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 23.57 | -0.23 % | $ 4.06 B | ||
|
OraSure Technologies
OSUR
|
$ 2.63 | -1.13 % | $ 196 M | ||
|
Pro-Dex
PDEX
|
$ 41.51 | 0.51 % | $ 136 M | ||
|
Predictive Oncology
POAI
|
$ 6.83 | 1.08 % | $ 37.2 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.63 | -0.61 % | $ 703 M | ||
|
Repligen Corporation
RGEN
|
$ 166.85 | 0.26 % | $ 9.3 M | ||
|
ResMed
RMD
|
$ 252.15 | 0.49 % | $ 36.8 B | ||
|
BioLife Solutions
BLFS
|
$ 24.8 | -0.6 % | $ 1.14 B | ||
|
STERIS plc
STE
|
$ 258.0 | -1.03 % | $ 25.4 B | ||
|
Stereotaxis
STXS
|
$ 2.53 | -2.13 % | $ 204 M | ||
|
Retractable Technologies
RVP
|
$ 0.76 | -2.53 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
$ 22.06 | -1.96 % | $ 1.08 B | ||
|
Teleflex Incorporated
TFX
|
$ 112.75 | 2.49 % | $ 5.28 B | ||
|
Utah Medical Products
UTMD
|
$ 59.83 | 1.87 % | $ 217 M | ||
|
West Pharmaceutical Services
WST
|
$ 275.51 | 0.1 % | $ 20.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 12.76 | 2.2 % | $ 2.59 B |